KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Goodwill & Intangibles (2016 - 2025)

Biomarin Pharmaceutical's Goodwill & Intangibles history spans 17 years, with the latest figure at $410.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Goodwill & Intangibles fell 9.18% year-over-year to $410.0 million, compared with a TTM value of $410.0 million through Dec 2025, down 9.18%, and an annual FY2025 reading of $410.0 million, down 9.18% over the prior year.
  • Goodwill & Intangibles for Q4 2025 was $410.0 million at Biomarin Pharmaceutical, down from $429.3 million in the prior quarter.
  • The five-year high for Goodwill & Intangibles was $602.1 million in Q1 2021, with the low at $410.0 million in Q4 2025.
  • Average Goodwill & Intangibles over 5 years is $508.3 million, with a median of $502.6 million recorded in 2023.
  • Year-over-year, Goodwill & Intangibles skyrocketed 163.62% in 2021 and then decreased 10.44% in 2023.
  • Tracing BMRN's Goodwill & Intangibles over 5 years: stood at $584.9 million in 2021, then decreased by 8.56% to $534.8 million in 2022, then decreased by 8.2% to $490.9 million in 2023, then decreased by 8.03% to $451.5 million in 2024, then decreased by 9.18% to $410.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Goodwill & Intangibles are $410.0 million (Q4 2025), $429.3 million (Q3 2025), and $435.8 million (Q2 2025).